Freeline Therapeutics Holdings PLC expected to post a loss of 28 cents a share - Earnings Preview

Freeline Therapeutics Holdings

31/03/2023 12:03

* Freeline Therapeutics Holdings PLC  FRLN.OQ   FRLN.O  is
expected to show no change in quarterly revenue when it reports 
results on April 4. 
    * 
    * ​Refinitiv's mean analyst estimate for Freeline
Therapeutics
Holdings PLC is for a loss of 28 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Freeline
Therapeutics Holdings PLC is $3​, above​ its last closing price
of $0.44. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.44       -0.44      -0.20     Beat    54.9
 Jun. 30 2022  -0.49       -0.51      -0.32     Beat    36.8
 Mar. 31 2022  -0.61       -0.60      -0.63     Missed  -4.1​
 Dec. 31 2021  -0.75       -0.68      -0.96     Missed  -41.2
 ​​Sep.        -1.02       -1.01      -0.86     Beat    15.1
 30 2021                                                
 Jun. 30 2021  -0.97       -0.97      -1.12     Missed  -15.7​
 Mar. 31 2021  -0.77       -0.78      -0.98     Missed  -25.2
 Dec. 31 2020              -0.70      -0.88     Missed  -24.8
 This summary was machine generated March 31 at 11:03 GMT.  All
figures in US dollars  unless otherwise stated